Axsome Therapeutics (AXSM) Reports Q1 2026 Earnings with Strong Revenue Growth and FDA Approval for AUVELITY
Axsome Therapeutics (AXSM) reported Q1 2026 earnings with total revenue of $191.2 million, a 57% year-over-year increase driven by its products AUVELITY, SUNOSI, and SYMBRAVO. The company received FDA approval for AUVELITY to treat agitation associated with Alzheimer's disease, and management now projects at least $8 billion in annual peak revenue for AUVELITY.
Tickers: $AXSM
Topics: Earnings Report FDA Approval Market Access Product Launch Revenue Growth